Highlights•The expression of TRIM37 was significantly higher in GBC tissues and associated with poor prognosis of GBC patients.•TRIM37 promotes GBC development by activating Wnt/β-catenin signaling through the degradation of Axin1.•TRIM37 contributes to the development of GBC and provides an important biomarker for predicting GBC prognosis and an effective target for therapeutic intervention.